FDA pharmacologic class
Vascular Endothelial Growth Factor Inhibitor
5 medicines are in FDA's class of vascular endothelial growth factor inhibitors: bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab-maly (Alymsys) and aflibercept-mrbb (Ahzantive). 0 of the 5 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are vascular endothelial growth factor inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Bevacizumab | Zirabev, Avastin, Vegzelma | none listed | n/a | No | No current entry | 3 |
| Ranibizumab | Cimerli, Lucentis, Byooviz | none listed | n/a | No | No current entry | 1 |
| Aflibercept | Eylea, Zaltrap, Pavblu | none listed | n/a | No | No current entry | 2 |
| Bevacizumab-maly | Alymsys | none listed | n/a | No | No current entry | 0 |
| Aflibercept-mrbb | Ahzantive | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)